Economic evaluation of pneumococcal conjugate vaccination in The Gambia

BMC Infectious Diseases

Table 3 Base-case results using a 9-valent pneumococcal conjugate vaccine (PCV9)

Model outcomes	No vaccination	Vaccination (PCV9)	Reduction
Pneumonia (primary endpoint)	5,039	3,635	27.9%
Pneumonia (non-primary endpoint)	25,123	25,758	-2.5%
Pneumonia (all endpoints)	30,161	29,393	2.5%
Meningitis	46	40	13.2%
Sepsis	21	18	13.2%
Hospitalization (primary endpoint pneumonia)	2,670	1,926	27.9%
Outpatient visit (primary endpoint pneumonia)	2,368	1,708	27.9%
Hospitalization (all endpoints of pneumonia)	7,519	6,898	8.3%
Hospitalization (all diseases)	7,586	6,956	8.3%
Pneumonia (primary endpoint) deaths	151	109	27.9%
Pneumonia (non-primary endpoint) deaths	276	283	-2.5%
Pneumonia (all endpoints) deaths	428	392	8.2%
Meningitis deaths	16	14	14.7%
Sepsis deaths	7	6	13.1%
DALYs (K = 0)^a	182,630	181,630	0.5%
Costs^a (2005 US$)	233,100	902,040	--
ICER (2005 US$/DALY averted)	--	670	--
ICER expressed as % per capita GDP^b		190%

DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio.
^a discounted at 3%.
^b $360 (in 2005 US$) in The Gambia for 2008.

ISSN: 1471-2334